Printer Friendly

BIOGEN REPORTS FIRST QUARTER EARNINGS OF 2 CENTS PER SHARE

 BIOGEN REPORTS FIRST QUARTER EARNINGS OF 2 CENTS PER SHARE
 CAMBRIDGE, Mass., April 10 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) today reported net income of $814,000 or 2 cents per share for the three months ended March 31, 1992. Revenues for the quarter were $19,122,000. For the first quarter last year, the company reported net income after preferred dividends of $1,409,000 or 5 cents per share, based on revenues of $18,065,000.
 Product-based revenues grew in excess of 10 percent over the first quarter of 1991 and accounted for 81 percent of total revenues in this year's first quarter. Research and development expenses increased by nearly 25 percent over the same period last year. The increased expenditures are largely being driven by the expansion of clinical trial programs and also reflect a charge of approximately $2 million related to the upgrade of Biogen's production facilities.
 Jim Vincent, Biogen chairman and chief executive officer, remarked, "Biogen's current revenue stream shows continued potential for growth,
especially in the Intron(R) A and hepatitis B vaccine markets. Our strategy is to devote resources to aggressively developing our most promising compounds, particularly hirulog and beta interferon, in preparation for bringing them successfully to market."
 Biogen, Inc., headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS and certain cancers.
 BIOGEN INC.
 Financial Results for First Quarter 1992
 (amounts in thousands, except per share data)
 Three months ended
 March 31,
 1992 1991
 Revenues
 Royalties and product sales $15,541 $14,120
 Research & development
 contracts 600 1,750
 Interest 2,981 2,195
 Total revenues 19,122 18,065
 Expenses
 Cost of sales 872 768
 Research & development 13,203 10,575
 General & administrative 3,894 3,444
 Other 249 323
 Total expenses 18,218 15,110
 Income before income taxes 904 2,955
 Income taxes 90 80
 Net income $814 $2,875
 Preferred stock dividends --- $1,466
 Earnings applicable to
 common stock $814 $1,409
 Earnings per share of
 common stock 2 cents 5 cents
 Average number of shares
 outstanding 34,130 27,110
 -0- 4/10/92
 /CONTACT: Kathryn R. Bloom, director of communications, 617-252- 9851, or Amy D. Seltzer, director of investor relations, 617-252-9873, both of Biogen/
 (BGEN) CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: ERN


EG -- NE007 -- 7131 04/10/92 10:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 10, 1992
Words:440
Previous Article:ARIANESPACE TO LAUNCH TWO SATELLITES FOR JAPANESE TELECOMS GIANT NTT
Next Article:JAPANESE BANK STRUCTURED RATINGS ON FITCHALERT NEGATIVE -- FITCH FINANCIAL WIRE --


Related Articles
BIOGEN REPORTS FIRST QUARTER EARNINGS OF 2 CENTS PER SHARE
BIOGEN REPORTS FOURTH QUARTER AND 1992 RESULTS
BIOGEN REPORTS SECOND QUARTER 1993 EARNINGS OF $5.6 MILLION VS. $0.7 MILLION IN SECOND QUARTER 1992

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters